A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Lebrikizumab (Primary) ; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical; Roche
- 20 Jul 2017 Planned End Date changed from 14 Nov 2017 to 15 Nov 2017.
- 20 Jul 2017 Planned primary completion date changed from 14 Nov 2017 to 15 Nov 2017.
- 14 Jul 2017 Planned End Date changed from 15 Nov 2017 to 14 Nov 2017.